The Need for Pediatric Drug Development.
作者信息
Ward Robert M, Benjamin Daniel K, Davis Jonathan M, Gorman Richard L, Kauffman Ralph, Kearns Gregory L, Murphy Mary Dianne, Sherwin Catherine M T
机构信息
Department of Pediatrics, University of Utah, School of Medicine, Salt Lake City, UT.
Duke Clinical Research Institute, Duke University, Durham, NC.
出版信息
J Pediatr. 2018 Jan;192:13-21. doi: 10.1016/j.jpeds.2017.08.011. Epub 2017 Sep 21.
Abstract
摘要
相似文献
1
The Need for Pediatric Drug Development.
J Pediatr. 2018 Jan;192:13-21. doi: 10.1016/j.jpeds.2017.08.011. Epub 2017 Sep 21.
2
50 Years Ago in The Journal of Pediatrics: Editorial Comment: Therapeutic Orphans.
J Pediatr. 2018 Jan;192:59. doi: 10.1016/j.jpeds.2017.07.017.
3
Pediatric Drug Development: Outlook for Science-Based Innovation.
Clin Pharmacol Ther. 2018 Mar;103(3):376-378. doi: 10.1002/cpt.1001. Epub 2018 Jan 31.
4
Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
Semin Perinatol. 2015 Nov;39(7):530-1. doi: 10.1053/j.semperi.2015.08.006. Epub 2015 Oct 9.
5
Future of pediatric therapeutics: reauthorization of BPCA and PREA.
Clin Pharmacol Ther. 2007 Apr;81(4):477-9. doi: 10.1038/sj.clpt.6100109.
6
Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
Clin Pharmacol Ther. 2020 Nov;108(5):1018-1025. doi: 10.1002/cpt.1886. Epub 2020 Jun 22.
7
Pediatric Antibacterial and Antifungal Trials From 2007 to 2017.
Pediatrics. 2018 Sep;142(3). doi: 10.1542/peds.2017-1849.
8
Dermatology Drugs for Children-U.S. Food and Drug Administration Perspective.
Dermatol Clin. 2022 Jul;40(3):289-296. doi: 10.1016/j.det.2022.02.004. Epub 2022 Jun 1.
9
[What's new in pediatric pharmacology?].
Arch Pediatr. 2000 Dec;7(12):1330-8. doi: 10.1016/s0929-693x(00)00152-4.
10
Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development.
Ther Innov Regul Sci. 2019 Sep;53(5):609-614. doi: 10.1177/2168479019837522. Epub 2019 Apr 14.
引用本文的文献
1
The Destructive Cycle in Bronchopulmonary Dysplasia: The Rationale for Systems Pharmacology Therapeutics.
Antioxidants (Basel). 2025 Jul 10;14(7):844. doi: 10.3390/antiox14070844.
2
Impact of China's Drug Review and Approval System Reform on Pediatric Drugs: an Analysis Based on Registration Data from 2015 to 2024.
Ther Innov Regul Sci. 2025 Jul 16. doi: 10.1007/s43441-025-00842-7.
3
Understudied Populations in Radiation Exposure Research: Needs, Challenges, and Mitigation Strategies.
Radiat Res. 2025 Jun 4. doi: 10.1667/RADE-24-00263.1.
4
Requirements and special considerations for drug trials with children across six jurisdictions: 1. Clinical trial application review in the regulatory approval process.
Front Med (Lausanne). 2025 Apr 15;12:1542408. doi: 10.3389/fmed.2025.1542408. eCollection 2025.
5
Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals.
World J Methodol. 2024 Jun 20;14(2):92371. doi: 10.5662/wjm.v14.i2.92371.
6
Paediatric Drug Development in China: Current Status and Future Prospects.
Paediatr Drugs. 2024 Sep;26(5):555-563. doi: 10.1007/s40272-024-00636-8. Epub 2024 Jun 5.
7
Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.
Orphanet J Rare Dis. 2024 Feb 25;19(1):86. doi: 10.1186/s13023-024-03097-x.
8
Off-Label Prescribing in Pediatric Population-Literature Review for 2012-2022.
Pharmaceutics. 2023 Nov 21;15(12):2652. doi: 10.3390/pharmaceutics15122652.
9
Diagnostic challenge: A pediatric patient with severe obesity and complications of imminent death.
Obes Pillars. 2023 Jun 25;7:100077. doi: 10.1016/j.obpill.2023.100077. eCollection 2023 Sep.
10
Complex and alternate consent pathways in clinical trials: methodological and ethical challenges encountered by underserved groups and a call to action.
Trials. 2023 Feb 28;24(1):151. doi: 10.1186/s13063-023-07159-6.
本文引用的文献
1
Pediatric Medicine Development: An Overview and Comparison of Regulatory Processes in the European Union and United States.
Ther Innov Regul Sci. 2017 May 1;51(3):360-371. doi: 10.1177/2168479017696265.
2
Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.
Pediatr Res. 2017 May;81(5):692-711. doi: 10.1038/pr.2016.221. Epub 2016 Nov 3.
3
Challenges and opportunities to enhance global drug development in neonates.
Curr Opin Pediatr. 2017 Apr;29(2):149-152. doi: 10.1097/MOP.0000000000000463.
4
Newborns still lack drug data to guide therapy.
Br J Clin Pharmacol. 2016 Dec;82(6):1410-1411. doi: 10.1111/bcp.13074. Epub 2016 Oct 3.
5
The International Neonatal Consortium: collaborating to advance regulatory science for neonates.
Pediatr Res. 2016 Oct;80(4):462-4. doi: 10.1038/pr.2016.119. Epub 2016 Jun 8.
6
Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions: A White Paper From the NICHD Diabetes Working Group.
Diabetes Care. 2016 Mar;39(3):323-9. doi: 10.2337/dc15-1649.
7
Special article: 2014 Pediatric Clinical Trials Forum.
Pediatr Res. 2016 Apr;79(4):662-9. doi: 10.1038/pr.2015.255. Epub 2015 Dec 9.
8
The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research.
J Am Coll Dent. 2014 Summer;81(3):4-13.
9
Sponsors meet scientists to speed pediatric medicines development.
Sci Transl Med. 2015 Mar 18;7(279):279fs11. doi: 10.1126/scitranslmed.aaa2045.
10
Diseases of pulmonary surfactant homeostasis.
Annu Rev Pathol. 2015;10:371-93. doi: 10.1146/annurev-pathol-012513-104644.
Zotero 插件